FTO and leukemia: developed two highly potent in vitro anti-leukemia FTO inhibitors, CS1 and CS2, which limit the self-renewal of cancer stem cells, increasing the sensitivity of leukemia cells to T-cell toxicity and overcoming hypomethylated drug-induced immune evasion (155).